Ying Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ying Wang has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
- Amanda W. Dombrowski
AbbVie, Inc. , 1 N Waukegan Rd
6 shared publications - Noah P. Tu
AbbVie, Inc. 1 N Waukegan Rd, North Chicago, Illinois 60064, United States
6 shared publications Stevan W. Djuric
Discovery Chemistry and Technology AbbVie 1 North Waukegan Road North Chicago IL 60064 USA
6 shared publications- Alexander J. Rago
AbbVie, Inc.
4 shared publications - Ana Luisa Aguirre
AbbVie, Inc. , 1 N Waukegan Rd
3 shared publications - Anil Vasudevan
AbbVie Inc. , 1 North Waukegan Road , North Chicago , Illinois 60064 , United States
3 shared publications
Latest Publications
- 3 September 2026
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 91 (37) , 12471-12480
The Development and Application of a ChemBead-Enabled On-DNA HTE Platform for Challenging C–N Couplings
In this work, we present the creation and implementation of a ChemBead-enabled, on-DNA high-throughput experimentation (HTE) platform to identify more general and mild reaction conditions for challenging C–N couplings. The platform was developed by adapting our small-molecule system to address the inherent challenges of on-DNA chemistry. The results generated by the platform were compared to the standard operating procedure for DNA-encoded library (DEL) production to ensure the translation of any promising conditions. The platform was used to discover a condition that has not been previously reported for on-DNA C–N coupling. This condition is best suited for secondary amines and select primary amines on short DNA substrates; primary aliphatic amines on elongated DNA-tagged aryl halide conjugates remain a challenge. This newly identified condition can be applied to DNA-encoded library constructions.
- 3 September 2026
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 91 (37) , 12471-12480
The Development and Application of a ChemBead-Enabled On-DNA HTE Platform for Challenging C–N Couplings
In this work, we present the creation and implementation of a ChemBead-enabled, on-DNA high-throughput experimentation (HTE) platform to identify more general and mild reaction conditions for challenging C–N couplings. The platform was developed by adapting our small-molecule system to address the inherent challenges of on-DNA chemistry. The results generated by the platform were compared to the standard operating procedure for DNA-encoded library (DEL) production to ensure the translation of any promising conditions. The platform was used to discover a condition that has not been previously reported for on-DNA C–N coupling. This condition is best suited for secondary amines and select primary amines on short DNA substrates; primary aliphatic amines on elongated DNA-tagged aryl halide conjugates remain a challenge. This newly identified condition can be applied to DNA-encoded library constructions.
- Open Access
- 1 January 2026
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 17 (25) , 12334-12345
A machine learning-based workflow for transaminase selection
Predictive ML models enable the rank-ordering of transaminase enzymes for a given substrate based on their predicted reactivities, thus expediting enzyme selection for chiral amine synthesis in medicinal chemistry research.
- 1 January 2026
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 17 (25) , 12334-12345
Open AccessA machine learning-based workflow for transaminase selection
Predictive ML models enable the rank-ordering of transaminase enzymes for a given substrate based on their predicted reactivities, thus expediting enzyme selection for chiral amine synthesis in medicinal chemistry research.
- 23 October 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (21) , 21999-22008
Design and Implementation of a High-Throughput Experimentation Platform to Accelerate Drug Discovery
Herein, we describe the development of the high-throughput experimentation platform and function in AbbVie’s Discovery Chemistry organization. The strategy and approach tailored specifically to medicinal chemistry needs are discussed. Additionally, we disclose the top reaction conditions for the most requested transformations obtained by analysis of the combined data set generated by the platform over five years.
- 23 October 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (21) , 21999-22008
Design and Implementation of a High-Throughput Experimentation Platform to Accelerate Drug Discovery
Herein, we describe the development of the high-throughput experimentation platform and function in AbbVie’s Discovery Chemistry organization. The strategy and approach tailored specifically to medicinal chemistry needs are discussed. Additionally, we disclose the top reaction conditions for the most requested transformations obtained by analysis of the combined data set generated by the platform over five years.
- 4 September 2025
- Published by Royal Society of Chemistry (RSC) in Reaction Chemistry & Engineering
- Vol. 10 (12) , 2982-2990
High-throughput experimentation for photoredox cross-couplings using the automated photoredox optimization reactor
High-throughput experimentation enables rapid optimization of challenging photoredox cross-couplings by leveraging reaction miniaturization, novel automated processes, and advanced high-throughput analytical methods.
- 4 September 2025
- Published by Royal Society of Chemistry (RSC) in Reaction Chemistry & Engineering
- Vol. 10 (12) , 2982-2990
High-throughput experimentation for photoredox cross-couplings using the automated photoredox optimization reactor
High-throughput experimentation enables rapid optimization of challenging photoredox cross-couplings by leveraging reaction miniaturization, novel automated processes, and advanced high-throughput analytical methods.
- 28 July 2025
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 16 (8) , 1473-1479
Evolving Landscape: Accounts of Academic-Industrial Collaborations in Chemistry Technology
Academic-industrial collaborations in the pharmaceutical industry have led to advances in novel science and pipeline goals. These partnerships find success by leveraging the resources and expertise of the industrial sector with the creativity and depth of knowledge of academic researchers. Here, we discuss case studies of several past and present academic-industrial collaborations from a chemistry technology group and their evolution from operating under funding-driven models to more reciprocal exchanges of effort and information. Effective partnerships depend on the careful selection of the right collaborators and projects, and they require clear communication, alignment of interests, and patience throughout the phases of a collaboration. Research areas of high interest for academic collaborations are discussed, such as advancements in synthetic methodology and drug discovery platforms such as DNA-encoded libraries and PROTACS.
- 28 July 2025
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 16 (8) , 1473-1479
Evolving Landscape: Accounts of Academic-Industrial Collaborations in Chemistry Technology
Academic-industrial collaborations in the pharmaceutical industry have led to advances in novel science and pipeline goals. These partnerships find success by leveraging the resources and expertise of the industrial sector with the creativity and depth of knowledge of academic researchers. Here, we discuss case studies of several past and present academic-industrial collaborations from a chemistry technology group and their evolution from operating under funding-driven models to more reciprocal exchanges of effort and information. Effective partnerships depend on the careful selection of the right collaborators and projects, and they require clear communication, alignment of interests, and patience throughout the phases of a collaboration. Research areas of high interest for academic collaborations are discussed, such as advancements in synthetic methodology and drug discovery platforms such as DNA-encoded libraries and PROTACS.
- 2 June 2025
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 16 (6) , 916-924
A Miniaturized Chemical High Throughput Experimentation Plate to Enable Late-Stage Oxidation Screening and Scale-up
Chemical methods for Late-Stage Oxidation (LSO) of advanced and complex molecules remain a highly relevant topic, with new and improved methods being reported annually. Despite the growing number of methodologies, the scope and limitations of these methods in bioactive molecules is largely unknown. We have designed a High-Throughput Experimentation (HTE) plate based on validated LSO methods, capable of screening compounds using only a few milligrams, to enhance our Late-Stage Functionalization (LSF) platform. Various projects at AbbVie have benefited from this plate, generating essential data for programs and creating new analogs for comprehensive Structure-Activity Relationship (SAR) analysis. We demonstrated the transformative capabilities of this approach by screening nine well-known drugs and analyzed the oxidized derivatives. This report highlights how this overlooked transformation can be an effective synthetic tool for medicinal chemistry.
- 2 June 2025
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 16 (6) , 916-924
A Miniaturized Chemical High Throughput Experimentation Plate to Enable Late-Stage Oxidation Screening and Scale-up
Chemical methods for Late-Stage Oxidation (LSO) of advanced and complex molecules remain a highly relevant topic, with new and improved methods being reported annually. Despite the growing number of methodologies, the scope and limitations of these methods in bioactive molecules is largely unknown. We have designed a High-Throughput Experimentation (HTE) plate based on validated LSO methods, capable of screening compounds using only a few milligrams, to enhance our Late-Stage Functionalization (LSF) platform. Various projects at AbbVie have benefited from this plate, generating essential data for programs and creating new analogs for comprehensive Structure-Activity Relationship (SAR) analysis. We demonstrated the transformative capabilities of this approach by screening nine well-known drugs and analyzed the oxidized derivatives. This report highlights how this overlooked transformation can be an effective synthetic tool for medicinal chemistry.
- Open Access
- 20 May 2024
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 146 (22) , 15070-15084
Incorporating Synthetic Accessibility in Drug Design: Predicting Reaction Yields of Suzuki Cross-Couplings by Leveraging AbbVie’s 15-Year Parallel Library Data Set
Despite the increased use of computational tools to supplement medicinal chemists' expertise and intuition in drug design, predicting synthetic yields in medicinal chemistry endeavors remains an unsolved challenge. Existing design workflows could profoundly benefit from reaction yield prediction, as precious material waste could be reduced, and a greater number of relevant compounds could be delivered to advance the design, make, test, analyze (DMTA) cycle. In this work, we detail the evaluation of AbbVie's medicinal chemistry library data set to build machine learning models for the prediction of Suzuki coupling reaction yields. The combination of density functional theory (DFT)-derived features and Morgan fingerprints was identified to perform better than one-hot encoded baseline modeling, furnishing encouraging results. Overall, we observe modest generalization to unseen reactant structures within the 15-year retrospective library data set. Additionally, we compare predictions made by the model to those made by expert medicinal chemists, finding that the model can often predict both reaction success and reaction yields with greater accuracy. Finally, we demonstrate the application of this approach to suggest structurally and electronically similar building blocks to replace those predicted or observed to be unsuccessful prior to or after synthesis, respectively. The yield prediction model was used to select similar monomers predicted to have higher yields, resulting in greater synthesis efficiency of relevant drug-like molecules.
- 20 May 2024
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 146 (22) , 15070-15084
Open AccessIncorporating Synthetic Accessibility in Drug Design: Predicting Reaction Yields of Suzuki Cross-Couplings by Leveraging AbbVie’s 15-Year Parallel Library Data Set
Despite the increased use of computational tools to supplement medicinal chemists' expertise and intuition in drug design, predicting synthetic yields in medicinal chemistry endeavors remains an unsolved challenge. Existing design workflows could profoundly benefit from reaction yield prediction, as precious material waste could be reduced, and a greater number of relevant compounds could be delivered to advance the design, make, test, analyze (DMTA) cycle. In this work, we detail the evaluation of AbbVie's medicinal chemistry library data set to build machine learning models for the prediction of Suzuki coupling reaction yields. The combination of density functional theory (DFT)-derived features and Morgan fingerprints was identified to perform better than one-hot encoded baseline modeling, furnishing encouraging results. Overall, we observe modest generalization to unseen reactant structures within the 15-year retrospective library data set. Additionally, we compare predictions made by the model to those made by expert medicinal chemists, finding that the model can often predict both reaction success and reaction yields with greater accuracy. Finally, we demonstrate the application of this approach to suggest structurally and electronically similar building blocks to replace those predicted or observed to be unsuccessful prior to or after synthesis, respectively. The yield prediction model was used to select similar monomers predicted to have higher yields, resulting in greater synthesis efficiency of relevant drug-like molecules.
- 5 March 2024
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 89 (22) , 16070-16092
At the Speed of Light: The Systematic Implementation of Photoredox Cross-Coupling Reactions for Medicinal Chemistry Research
The adoption of new and emerging techniques in organic synthesis is essential to promote innovation in drug discovery. In this Perspective, we detail the strategy we used for the systematic deployment of photoredox-mediated, metal-catalyzed cross-coupling reactions in AbbVie's medicinal chemistry organization, focusing on topics such as assessment, evaluation, implementation, and accessibility. The comprehensive evaluation of photoredox reaction setups and published methods will be discussed, along with internal efforts to build expertise and photoredox high-throughput experimentation capabilities. We also highlight AbbVie's academic-industry collaborations in this field that have been leveraged to develop new synthetic strategies, along with discussing the internal adoption of photoredox cross-coupling reactions. The work described herein has culminated in robust photocatalysis and cross-coupling capabilities which are viewed as key platforms for medicinal chemistry research at AbbVie.
- 5 March 2024
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 89 (22) , 16070-16092
At the Speed of Light: The Systematic Implementation of Photoredox Cross-Coupling Reactions for Medicinal Chemistry Research
The adoption of new and emerging techniques in organic synthesis is essential to promote innovation in drug discovery. In this Perspective, we detail the strategy we used for the systematic deployment of photoredox-mediated, metal-catalyzed cross-coupling reactions in AbbVie's medicinal chemistry organization, focusing on topics such as assessment, evaluation, implementation, and accessibility. The comprehensive evaluation of photoredox reaction setups and published methods will be discussed, along with internal efforts to build expertise and photoredox high-throughput experimentation capabilities. We also highlight AbbVie's academic-industry collaborations in this field that have been leveraged to develop new synthetic strategies, along with discussing the internal adoption of photoredox cross-coupling reactions. The work described herein has culminated in robust photocatalysis and cross-coupling capabilities which are viewed as key platforms for medicinal chemistry research at AbbVie.
- 16 March 2023
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 14 (4) , 521-529
ChemBeads-Enabled Photoredox High-Throughput Experimentation Platform to Improve C(sp2)–C(sp3) Decarboxylative Couplings
Enthusiasm surrounding nickel/photoredox C(sp2)-C(sp3) cross-couplings is very high; however, these methods are sometimes challenged by complex drug-like substrates in discovery chemistry. In our hands this has been especially true of the decarboxylative coupling, which has lagged behind other photoredox couplings in internal adoption and success. Herein, the development of a photoredox high-throughput experimentation platform to optimize challenging C(sp2)-C(sp3) decarboxylative couplings is described. Chemical-coated glass beads (ChemBeads) and a novel parallel bead dispenser are used to expedite the high-throughput experimentation process and identify improved coupling conditions. In this report, photoredox high-throughput experimentation is utilized to dramatically improve low-yielding decarboxylative C(sp2)-C(sp3) couplings, and libraries, using conditions not previously identified in the literature.
- 16 March 2023
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 14 (4) , 521-529
ChemBeads-Enabled Photoredox High-Throughput Experimentation Platform to Improve C(sp2)–C(sp3) Decarboxylative Couplings
Enthusiasm surrounding nickel/photoredox C(sp2)-C(sp3) cross-couplings is very high; however, these methods are sometimes challenged by complex drug-like substrates in discovery chemistry. In our hands this has been especially true of the decarboxylative coupling, which has lagged behind other photoredox couplings in internal adoption and success. Herein, the development of a photoredox high-throughput experimentation platform to optimize challenging C(sp2)-C(sp3) decarboxylative couplings is described. Chemical-coated glass beads (ChemBeads) and a novel parallel bead dispenser are used to expedite the high-throughput experimentation process and identify improved coupling conditions. In this report, photoredox high-throughput experimentation is utilized to dramatically improve low-yielding decarboxylative C(sp2)-C(sp3) couplings, and libraries, using conditions not previously identified in the literature.
- 15 November 2022
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 24 (46) , 8487-8492
Di(2-picolyl)amines as Modular and Robust Ligands for Nickel-Catalyzed C(sp2)–C(sp3) Cross-Electrophile Coupling
Ni-catalyzed aryl-alkyl coupling reactions are reliant on using a limited set of commercially available bidentate nitrogenous ligands to enable the reaction, because noncommercial analogues usually entail challenging syntheses. In this work, di(2-picolyl)amines (DPAs) are explored as an alternative modular ligand class for the nickel-catalyzed aryl-alkyl cross-electrophile coupling. Novel DPA ligands were synthesized directly from inexpensive amine and pyridine building blocks in a single step. This facile synthetic route enabled the parallel synthesis of DPA ligands with varied steric and electronic properties. From this collection of ligands, a few robust ligands for C(sp2)-C(sp3) cross-electrophile coupling were identified and tested in the cross-coupling of a range of diverse molecules, including model examples for late-stage functionalization.
- 15 November 2022
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 24 (46) , 8487-8492
Di(2-picolyl)amines as Modular and Robust Ligands for Nickel-Catalyzed C(sp2)–C(sp3) Cross-Electrophile Coupling
Ni-catalyzed aryl-alkyl coupling reactions are reliant on using a limited set of commercially available bidentate nitrogenous ligands to enable the reaction, because noncommercial analogues usually entail challenging syntheses. In this work, di(2-picolyl)amines (DPAs) are explored as an alternative modular ligand class for the nickel-catalyzed aryl-alkyl cross-electrophile coupling. Novel DPA ligands were synthesized directly from inexpensive amine and pyridine building blocks in a single step. This facile synthetic route enabled the parallel synthesis of DPA ligands with varied steric and electronic properties. From this collection of ligands, a few robust ligands for C(sp2)-C(sp3) cross-electrophile coupling were identified and tested in the cross-coupling of a range of diverse molecules, including model examples for late-stage functionalization.